 REDWOOD CITY, Calif., April 20, 2021 GLOBE NEWSWIRE -- Biomea Fusion, Inc. Biomea Nasdaq: BMEA, a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, today announced the closing of its initial public offering of 9,000,000 shares of its common stock at a public offering price of 17.00 per share. All of the shares of common stock were offered by Biomea. Biomeas common stock began trading on The Nasdaq Global Select Market on April 16, 2021 under the ticker symbol BMEA. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biomea, were 153.0 million. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions and offering expenses. 